Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lumos Pharma Inc
(NQ:
LUMO
)
2.830
-0.180 (-5.98%)
Streaming Delayed Price
Updated: 10:14 AM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lumos Pharma Inc
< Previous
1
2
Next >
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 15, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
August 01, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
July 23, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
June 04, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
May 20, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
May 14, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
May 09, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
April 18, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
March 25, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
March 20, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
March 07, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
February 26, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
February 05, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
January 04, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
November 21, 2023
Webinar to be Held December 6, 2023 at 1:30pm EST
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
November 20, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
November 07, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
November 07, 2023
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
September 26, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
September 14, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Participation in Investor Conferences in September
September 07, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
August 22, 2023
Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
August 09, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
July 26, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
July 12, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Departure of Chief Medical Officer
June 28, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
June 21, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
May 31, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
May 25, 2023
KOL Webinar to be held June 21, 2023 at 11:00 AM Eastern Time
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in World Orphan Drug Congress USA
May 22, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.